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Introduction
Circumcision is the oldest planned operative procedure in the history of the human
civilization, but there continues to be a lack of consensus and strong opposing views on
whether universal neonatal circumcision should be adopted as a public health measure.
The American Academy of Pediatrics 2012 guideline on male circumcision (MC),
reversed its prior stand stating that the “health benefits of newborn male circumcision
outweigh the risks” and justify access to the procedure if the parents so choose 1.
The following set of guidelines will investigate and provide evidence regarding the
benefits of neonatal MC, its potential complications and the care of the normal foreskin
in early childhood, adapted for the Canadian population and health care system. A more
comprehensive version of this guideline describing the detailed evidence to support the
proposed recommendations and including sections on MC trends, indications of pediatric
MC, cost analyses and training implications is provided in the web version of this
guideline (available at cuaj.ca). The evidence presented is classified according to the
Oxford system of evidence-based medicine, with a summary using the GRADE system 2.
Methods
Systematic literature searches were conducted in MEDLINE including Pre-MEDLINE
EMBASE, BIOSIS Previews®, Web of Science® – with Conference Proceedings, and the
Cochrane Central Register of Controlled Trials electronic bibliographic databases and
were restricted to either adult or pediatric studies (</> 18 years) (January 2000 to March
2013). An additional limited review was conducted till June 2016 to include any
subsequent significant studies. All searches were restricted to studies published in the
English language. The search strategy is described in the web version of the guideline.
After excluding duplicate records and non-relevant studies, a total of 233 studies out of
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2674 were included in this analysis, though some studies are only discussed in the
detailed version of this guideline.
Care of the normal foreskin in childhood and management of physiological phimosis
The prepuce arises from the coronal margin by a combination of folding and epithelial
outgrowth and has an outer and inner layer separated by Dartos fascia. At birth, the inner
foreskin is fused to the glans penis and should not be retracted until spontaneous
retraction occurs over the first few years of life. In the absence of clinical scarring
suggesting pathological phimosis (Fig. 1), history of recurrent urinary tract infections
(UTI’s) or balano-posthitis (Fig. 2), no intervention is required for physiological
phimosis. Ballooning of the foreskin during voiding is not associated with obstructed
voiding and is not an indication for circumcision 3. Vigorous retraction has the potential
to cause micro-tears leading to scarring and an iatrogenic true phimosis. Therefore,
normal foreskin care in early childhood starts once the foreskin is retractable and this
occurs at varying ages. Indications for urological consultation include suspicion of true
phimosis with evident scarring, Lichen sclerosis of the foreskin (Fig. 3), recurrent
episodes of balano-posthitis or recurrent UTI’s, and delayed retraction of the foreskin
past 8-10 years of age 4.
Treatment of physiological phimosis
Several observational studies and randomized trials have investigated the role of topical
steroids and preputial stretching in resolving physiologic phimosis. A recent metaanalysis and several RCT’s show significant success (60-80%) when using topical steroid
creams as a treatment modality for physiological phimosis 5-9. Success rates are not
dependent on steroid potency 10. Side effects are rare and there was no suppression of the
hypothalamic-pituitary-adrenal axis provided therapy was limited to 8 weeks for each
course 11. Success with this treatment modality, lies in differentiating physiologic and
true phimosis, active counseling and selecting patients when they are age-appropriate to
attempt this treatment modality. Physiological phimosis does not require treatment unless
the child has recurrent UTI’s or balano-posthitis. In some instances, in an older prepubertal child, topical steroid therapy can be initiated for persisting physiological
phimosis 4.
Recommendations (care of the normal foreskin and physiological phimosis):
1. Neonatal examination of the foreskin and urethral meatus should be part
of routine clinical assessment of all newborn boys. Continued
examination of the foreskin, without forcible retraction, is recommended
during yearly physical examinations to rule out pathological phimosis
and document natural preputial retraction (Level 5, Grade D).
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2. Persistent physiological phimosis in the absence of recurrent balanoposthitis or UTI’s is not an indication for circumcision [Level 5, Grade
D].
3. Topical steroids are the first line of treatment for physiological phimosis
with good success rates and low risk of complications (Level 1b/2b, Grade
A).
4. Moderately- low potency steroids (triamcinolone, clobetasone,
hydrocortisone, mometasone) have similar success compared to a highly
potent steroid (betamethasone) (Level 2b, Grade B).
5. Patient selection to ensure compliance, demonstrating the technique of
steroid application and retraction and continued retraction after initial
success is important to achieve success following topical steroid therapy
for physiological phimosis (Level 5 Grade D).
6. Recurrence of physiological phimosis is common if retraction is not
carried out after initial success and a repeat course of topical steroid
therapy is recommended (Level 2b/3 Grade C).
Circumcision and risk of urinary tract infections
Prior evidence indicates that neonatal MC decreases the risk of UTI’s12, but there is
ongoing debate on the magnitude and duration of this effect. The role of circumcision in
preventing UTI’s must be studied in 2 distinct subgroups: males with normal urinary
tracts and those with recurrent UTI’s or urological conditions predisposing to UTI’s like
antenatal hydronephrosis, vesico-ureteric reflux (VUR), posterior urethral valves,
neurogenic bladders and primary megaureters. In boys without predisposing urological
conditions, the estimated incidence of UTI in the first 10 years of life varies between 1 to
2% 12,13. In a meta-analysis of febrile infants (males and females 0-24 months), Shaikh et
al estimated the prevalence of UTI was 7 %, with males under 3 months having the
highest prevalence 14.
Boys with normal urinary tracts
Previous studies have shown that the risk of UTIs is increased in uncircumcised males 13,
15-21
. In a case-control study from Australia which included children with urological
abnormalities, Craig et al showed that the protective effects of MC in infants, was
marginally significant (OR 0.03 95% CI 0.06-1.1). However, this effect was not observed
beyond infancy (OR=0.2, 95% CI 0.01-3.7) 21. A systematic review (SR) by SinghGrewal supported the beneficial effects of MC on pediatric UTI risk (OR 0.13 95% CI
0.07-0.23) 16. Assuming a 1-2% circumcision complication rate and a 1% UTI risk in
normal infants, universal neonatal circumcision is hard to justify based on a number
needed to treat (NNT) of 11116. Even if we accept a lower complication rate of 0.2% and
a 2% UTI risk, given the effectiveness of UTI treatment, 6 UTI’s will be prevented at the
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expense of 1 MC complication. A recent SR conducted by Morris et al, calculated the
lifetime risk of a UTI to be 32% in uncircumcised males compared to 9% in circumcised
males 22. The authors suggested a lower NNT of 4.2 (95% CI 2.2-27) for preventing 1
UTI, albeit, over a lifetime.
Boys with abnormal urinary tract
In urological conditions like high grade VUR, posterior urethral valves, primary
megaureters the risk of UTI is higher. In patients with VUR, circumcision was more
effective than antibiotic prophylaxis alone or surgical correction in preventing UTIs and
the occurrence of new DMSA abnormalities 23-25. Similar results were seen in boys with
posterior urethral valves26 and infants with significant antenatal hydronephrosis27. In this
subset of boys, with a risk of recurrent UTI (assuming 10% UTI risk, the NNT is 11) and
for boys with urological abnormalities (assuming 30% UTI risk high grade VUR, the
NNT is 4), a circumcision should be considered 16. Topical steroid treatment of
physiological phimosis to allow retraction and hygiene or antibiotic prophylaxis are other
viable options for these children.
Recommendations (circumcision and UTIs):
1. Neonatal circumcision decreases the risk of UTI during early
childhood (Level 2a) but the overall risk of UTI is low in infant males
beyond 3 months of life and decreases further beyond infancy (Level
2b-4).
2. There is paucity of level-1 evidence to justify recommending universal
neonatal circumcision to prevent UTI’s in normal males.
3. A stronger effect of neonatal circumcision in preventing UTI’s in boys
with posterior urethral valves and significant antenatally detected
hydronephrosis has been demonstrated and therefore it is
recommended that a discussion regarding MC with the parents is
advisable for these neonates (Level 3-4 Grade C).
Circumcision and risk of sexually transmitted infections
A decreased risk of Human immunodeficiency virus (HIV) and other sexually transmitted
infections (STI’s) is the primary argument driving a change in risk-benefit assessment of
MC.
1. Human immunodeficiency virus (HIV)
A recent Public Health Agency of Canada reported an estimated HIV prevalence rate of
208 per 100,000 population, with an 11.4% increase compared to 2008 estimates 28. Men
who have sex with men (MSM) accounted for 47% of prevalent infections followed by
intra-venous drug users (17%) and heterosexual individuals (17.6%).
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Based on RCT’s conducted in high HIV prevalence sub-Saharan Africa, there is
clear Level 1 evidence that MC reduces the risk of HIV infection in heterosexual men
(Table 1) 29-31. In 2007, the WHO and UNAIDS recommended MC in HIV prevalent
areas in combination with the promotion of “ABC” (Abstinence, Behavior change and
correct and consistent Condom use) 29. The protective effect of circumcision against HIV
infection has been attributed to decreased coital trauma, decreases in prevalence of
Langerhans cells, as well as increased keratinization of the glans 32-34.
Female to male HIV transmission
Several RCT’s and a meta-analysis of 15 observational studies conducted in 2000,
supported a protective effect of MC against HIV infection (adjusted RR 0.42, 95% CI
0.34-0.54%) 29-31, 35, 36. A Cochrane review of the 3 African trials supported the finding
that MC is protective against female to male HIV transmission (IRR 0.5, 95% CI 0.340.72 at 1 year and IRR 0.46, 95% CI 0.34-0.62 at 2 years) 36.
Male to male HIV transmission
Evidence of an association between circumcision status and HIV infection in men who
have sex with men (MSM) is limited to observational studies, often not stratified by
receptive and insertive roles. It is believed that men who practice an insertive role could
likely benefit from MC while those who perform a receptive role may have little or no
protection. In a Cochrane review by Wiysonge et al (6 cohort, 14 cross-sectional, 1 casecontrol; 71,693 participants), risk for HIV acquisition in MSM males was not altered by
MC (OR 0.86, 95% CI 0.7-1.06) 37. In a subgroup analysis of men reporting an insertive
role, MC was found to be protective (OR 0.27, 95% CI 0.17-0.44). A previous metaanalysis by Millett et al in 2008, similarly concluded that MC is not protective against
MSM HIV transmission 38.
Male to female HIV transmission
MC can potentially decrease female partner HIV infection directly or indirectly by
reducing overall male prevalence of HIV at the population level. However, a Ugandan
RCT and a MA of observational studies found that MC did not provide any protective
effects against male to female HIV transmission 39, 40.
Several factors need to be considered to make appropriate recommendations for
our population. The MC rate in the 3 African countries ranged between 10-20% and HIV
prevalence was between 7-25%. In contrast, the Canadian MC rate is around 35-40% and
HIV prevalence is much lower leading to a potentially higher NNT. In addition, in
Canada, only a small proportion of HIV transmission is attributed to heterosexual
activity, and evidence suggests that MSM men are not protected by MC. Variations in
sexual practices, education, behavior (condom usage), differences in STI prevalence and
access to health care, are likely to modify the magnitude of the protective effects. In
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addition, the long- term effectiveness of MC beyond 2 years is available only for the
Ugandan trial 41. The possibility of behavioral disinhibition, leading to unsafe sexual
practices, which can potentially offset the protective effect of MC has been documented
in several follow-up studies of the African RCT’s 41, 42.
Recommendations (circumcision and HIV):
1. Female to male transmission: There is compelling evidence that MC
reduces the risk of HIV transmission from female partners to male
(Level 1 A evidence, Grade A recommendation). The magnitude of the
effect may not be similar to the African trials in Canada and is not
established for neonatal MC.
2. Male to male transmission: Based on current evidence, MC does not
provide protection for men who have sex with men (Level 2a
evidence).
3. Women partners: Based on current evidence, MC is not protective for
female partners (Level 2a-b evidence).
4. Based on current evidence, universal neonatal circumcision cannot be
recommended to prevent HIV infection (Grade B).
2. Human papilloma virus (HPV)
Human papilloma virus (HPV) is the most common STI worldwide and up to 75% of
Canadians will have at least one lifetime HPV infection. The effect of MC on HPV is
difficult to interpret as HPV infection can be transient and can affect multiple genital
areas. In addition, HPV prevalence, incidence, clearance and viral load are all potential
outcomes with differing health implications.
HPV in men
Two meta-analyses were conducted evaluating the effect of MC on HPV 43, 44. Albero et
al analyzed data from 14 observational studies and 2 RCTs 44. Accepting heterogeneity,
data from the 2 RCT’s, showed a strong inverse association between MC and high-risk
HPV prevalence (OR 0.67, 95% CI 0.54-0.82). The 14 prevalence studies showed a
similar pooled result of HPV prevalence. There was no association between MC and
incident HPV infections or clearance. A previous MA conducted by Larke et al, also
showed similar prevalence results (OR 0.57, 95% CI 0.45-0.71) 43. There was weak
evidence that MC was associated with decreased HPV incidence (RR 0.75, 95% CI 0.570.99) or clearance (RR 1.33, 95% CI 0.89-1.98).
HPV in female partners
Two trials conducted on HIV positive and negative men in Uganda analyzed transmission
of HPV to female partners 45, 46. In the first trial on HIV negative men, the prevalence of
HR-HPV infection in female partners was lower in the circumcised group (PRR 0.72,
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95% CI 0.60-0.85) 45. The clearance rate for all genotypes (except HPV 16) was
improved in females with circumcised partners (p=0.014). In a second trial on female
partners of HIV infected men, Tobian et al showed that MC was not associated with
lower HR-HPV prevalence (PRR=1.07, 95% CI 0.86-1.32) 46.
The benefits of MC on HPV prevalence and incidence has to be balanced against the
effectiveness of condom usage and HPV vaccination 47, 48.
Recommendations (circumcision and HPV):
1. HPV prevalence in men: Current evidence suggests a modest decrease in
HPV prevalence in the glans and coronal sulcus up to 2 years following
MC. (Level 1b evidence). The protective effect is partial, does not cover
all high- risk types and is weaker further away from the glans and
coronal sulcus. It is not clear whether this effect will persist into
adulthood following neonatal circumcision.
2. HPV clearance in men: There is no evidence (except a single RCT on HIV
negative men) that MC increases HPV clearance (Level 1b-2b evidence).
Theoretically, if MC increases clearance this may also inflate the impact
on HPV prevalence.
3. HPV incidence or acquisition in men: There is no convincing evidence to
suggest that MC decreases HPV acquisition or affects HPV incidence in
HIV positive or negative men (Level 1b-2b evidence).
4. HPV in female partners: MC possibly lowers prevalence, incidence and
clearance in female partners of HIV negative men (Level 1b-2b).
5. As a public health intervention, universal neonatal MC is not justifiable
given access to HPV vaccination and baseline socio-economic and
educational status (Grade B).
3. Non-ulcerative STIs, genital ulcer disease (GUD), and ulcerative STIs
The most common non- ulcerative STIs are Gonorrhea, Chlamydia and Trichomonas
infections. 2 RCT’s have addressed the role of MC in these infections 49, 50. In the Kenyan
study, there was no association between MC and non-ulcerative STIs (HR 0.64, 95% CI
0.50-0.82), though condom usage was protective 49. The South African trial showed
lower Trichomonas vaginalis infection in men in an as-treated analysis (Adjusted OR
0.47, 95% CI 0.25-0.92) 50. A MA of 30 observational studies failed to identify a
statistically significant association between non- ulcerative STI’s and MC 51. In another
prospective study, uncircumcised male partners had a higher risk of T. vaginalis infection
compared to circumcised partners of T. vaginalis infected women (OR 1.8, 95% CI 1.13.2) 52. In a prospective cohort study, MC did not have any protective effect on female
partners with regards to chlamydial, gonococcal and trichomonal infections 53.
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Herpes simplex virus (HSV), T pallidum (syphilis), H ducreyi (chancroid) and K
granulomatis (Donovanosis) are the common causes of genital ulcer disease (GUD).
Women and men with GUD and HSV-2 have a higher risk of acquiring or transmitting
HIV and conversely HIV infection increases the risk of GUD 54, 55. In a MA of
observational studies, MC was not associated with a decreased risk of HSV-2
seropositivity (RR 0.88, 95% CI 0.77-1.01) 56. There was a protective effect of MC on
syphilis seropositivity (RR 0.67, 95% CI 0.54-0.83) and the results for chancroid
infections was unclear. In HIV positive men, Tobian et al showed a lower risk of HSV 2
seroconversion in the circumcised group (Adjusted IRR 0.70, 95% CI 0.55-0.91) 57.
Consistent condom usage had a slightly higher protective effect. In HIV negative men,
the partial protective effect of MC against HSV-2 seroconversion was similar 58.
Multivariate analysis of South African RCT data, did not show a protective effect of MC
against HSV-2 seroincidence (IRR 0.68, 95% CI 0.38-1.22) 59. Mehta et al conducted an
RCT in Kenya and observed that HSV-2 incidence did not differ by circumcision status
(RR=0.94, 95% CI 0.7-1.25) but HSV-2 incident infection tripled the risk of HIV
acquisition 60.
Male to male HSV-2 transmission
In a Cochrane review of MSM males, MC did not have a protective role in preventing
syphilis (OR 0.96, 95% CI 0.82-1.13) or HSV-2 infections (OR 0.86, 95% CI 0.621.21) 61.
Non-ulcerative and ulcerative STIs in female partners
Gray et al followed HIV negative women married to men randomized to circumcised and
non-circumcised groups 62. Adjusted analyses suggested a 22% circumcision efficacy for
GUD (95% CI 0.61-0.99), a 45% efficacy for trichomonas (95% CI 0.34-0.89) and a 18%
efficacy for bacterial vaginosis (95% CI 0.74-0.91). In the Ugandan RCT on HIV
negative men, MC did not reduce the risk of HSV-2 acquisition in women partners 63.
Recommendations (circumcision and ulcerative/ non-ulcerative STIs):
1. Currently, there is no significant evidence to support the protective role
of MC in the acquisition of non-ulcerative STIs, though there may be a
protective effect on acquisition of Trichomonas infections (Level 2a-b
evidence, Grade B recommendation).
2. Currently, there is no significant evidence to support the protective role
of MC for males and females in the acquisition of ulcerative STI’s (Level
2-4 evidence, Grade C recommendation).
3. There is weak evidence of a partial protective effect of MC against HSV-2
infections in adult men following MC (Level 2a-b).
Circumcision and penile cancer
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In a MA of 8 studies, Larke et al showed that MC < 18 years of age was protective
against invasive penile cancer (OR 0.33, 95% CI 0.13-0.83) 64. In a matched case control
study, Tsen et al showed that phimosis was a strong risk factor for invasive penile
cancer 65. The protective effect of neonatal MC was not statistically significant when the
analysis was restricted to those who did not have a history of phimosis (OR 0.79, 95% CI
0.29-2.6). In another case control study from Denmark, penile cancer was associated with
phimosis (OR 4.9, 95% CI 1.85- 13.0), but not childhood circumcision (p=0.33) 66.
Daling et al also showed that after excluding patients with phimosis, lack of childhood
MC was not a risk factor for penile cancer 67. Penile cancer is strongly associated with
other risk factors like smoking, sexual practices and HPV infection, which can be
modified as opposed to universal MC 68.
Recommendations (circumcision and penile cancer):
1. Circumcision decreases the risk of penile cancer (Level 2-3).
2. However, given the low incidence of invasive penile cancer, the partial
protective effect of MC, and the availability of other preventive
strategies like HPV vaccination, condom usage and smoking cessation
programs, it is difficult to justify universal neonatal circumcision as a
preventive strategy for preventing penile cancer (Grade B).
3. Recognition and treatment of phimosis during regular health visits is
recommended to decrease the risk of penile cancer (Level 5, Grade D).
A genitourinary exam during puberty is recommended to ensure
preputial retractability and hygiene, and counsel regarding HPV
vaccination and safe sexual practices (Grade D).
Circumcision and prostate cancer
A recent case control study showed no protective effect of MC on prostate cancer (OR
0.87, 95% CI 0.74-1.02) 69. Another population-based study from Montreal also
demonstrated no significant overall protective effect of MC (or infant MC), but the
results where significant for men circumcised at ≥36 years of age (OR 0.55, 95% CI 0.30,
0.98) 70. A UK study did not find any significant correlation between MC and prostate
cancer 71.
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Recommendations (circumcision and prostate cancer):
1. There is no convincing evidence to suggest any protective effect of
MC against prostate cancer (Level 3- 4 evidence, Grade B).
Role of the foreskin in sensation and sexual function
There is ongoing controversy regarding the impact of circumcision on penile sensitivity
and sexual satisfaction. The primary question is whether loss of sensory nerves in the
foreskin or a possible decrease in glans sensitivity impacts sexual satisfaction, after
accounting for several confounders.
A recent meta-analysis included 10 studies to assess the impact of MC on sexual
function 72. There were no significant differences in sexual desire, dyspareunia,
premature ejaculation, ejaculation latency time or erectile dysfunctions between
circumcised and uncircumcised men. A secondary analysis of the Ugandan RCT showed
no long term differences in 4456 men for sexual desire, satisfaction and erectile
dysfunction 73. A similar trial from Kenya found contradictory results where
uncircumcised men reported an increase in sexual satisfaction 74. Intravaginal ejaculation
latency time (IELT) measured in a multinational study using a stopwatch and a blinded
timer showed that MC and condom use did not impact IELT 75.
Sexual function in partners
In an analysis of self-reported sexual experience in women partners of men before and
after circumcision, Kigozi et al showed no changes in 57% and improved sexual
satisfaction in 40% 73. In a study comparing uncircumcised and circumcised homosexual
men, Mao et al noted no differences in sexual difficulties or type of anal sex practiced 76.
Conclusions (circumcision and sexual function):
‒ There is lack of convincing evidence that adult male circumcision
impacts sexual function (Level 3-4 evidence, Grade C
recommendation).
Contraindications of neonatal circumcision
Neonatal circumcision should be performed on stable infants who do not have associated
congenital anomalies of the penis (Figs. 4‒9). In some off these conditions, MC can be
performed with appropriate technical modifications. Children with blood dyscrasias can
undergo MC, after appropriate treatment 77.
Anesthesia for neonatal circumcision
It is clear that neonatal circumcision must be performed with adequate anesthesia and
analgesia 78, 79. The adverse physiological and behavioral responses of inadequate pain
control in neonates is convincing, can lead to potential complications and alter long-term
pain responses in the neonate. Different methods used for providing anesthesia and/or
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analgesia during circumcision includes general anesthesia, topical anesthetics, penile
nerve blocks, oral sucrose-glucose administration, non-nutritive sucking, caudal block
and various combinations of the above 78, 79.
The 3 topical anesthetic options currently available include; lidocaine-prilocaine
5% cream (EMLA), tetracaine 4% gel and liposomal lidocaine 4% cream. Dorsal penile
(DPNB) and ring blocks are effective techniques to manage circumcision related pain.
Based on the Cochrane review by Brady-Fryer, a dorsal penile nerve block is the most
effective intervention for circumcision related pain with the caveat that the injection is
performed appropriately 78. Oral administration of sucrose, glucose, or parenteral
acetaminophen are not sufficient as sole measures for relieving the pain associated with
circumcision 78, 78, 80.
Recommendations for anesthesia and analgesia for neonatal circumcision:
1. A dorsal penile nerve block with a ring block, using proper technique,
is the most effective technique to provide anesthesia during a neonatal
circumcision (Level 1-2 evidence, Grade A recommendation).
2. Topical local anesthetics alone are inferior to nerve and ring blocks
and require an adequate time interval for efficacy and can be used as
an adjunct to penile blocks (Level 1-2 evidence, Grade A
recommendation).
3. Oral sucrose, non- nutritive sucking, music and other environmental
interventions should only be used as an adjunct to the above methods
(Level 1-3 evidence, Grade A recommendation).
Complications of circumcision
Neonatal circumcision is a safe surgical procedure and complications vary depending on
surgeon experience, technique used, age at MC, anatomic factors and the accuracy and
degree of post-operative reporting. Proper pre-operative assessment to recognize possible
complicating anatomic factors (penoscrotal webbing, ventral skin deficiency, suprapubic
fat pad) and adequate post-operative instructions to ensure retraction of the residual shaft
skin can prevent most complications.
Overall complication rates
Several studies have investigated the complication rates of neonatal MC 81-86. A recent
SR on complications of neonatal MC noted a wide 0-16% (median 2%) range of adverse
events in 16 prospective studies 81. The previous AAP Task Force on Circumcision
reported a complication rate of 0.2-0.6% 83, while the Canadian Pediatric Society
published complication rates as high as 2% 84.
Post-circumcision complications can be divided into early and late
complications 81-87. Early complications include bleeding, infection, glans
necrosis/amputation, delayed or early slippage of circumcision devices and very rarely
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death. Late complications include inadequate skin removal, inclusion cysts, adhesions
and skin bridges, suture sinus tracts, ventral curvature, secondary buried penis and
phimosis, urethro-cutaneous fistulae and meatal stenosis 87.
Conclusions regarding circumcision complications:
1. Complication rates following neonatal MC range between 0.6- 2%,
depending on accuracy of reporting. Given the variability in
complication rates and risk of delayed complications, the overall
complication rate for neonatal MC may be higher than quoted in the
literature (Level 2-4).
2. Operator experience, recognition of contraindications to MC,
technique used, age and patient related variables can potentially
impact complication rates [Level 4, Grade D].
Summary of results and recommendations
The benefits of neonatal MC have to be analyzed at the individual and societal level and
be objectively balanced against the complication rates, healthcare costs and implications
to our healthcare system. For a minority of Canadian neonates, there are well defined
advantages of a circumcision but the magnitude of these benefits is not clearly defined. In
addition, the protective benefits of MC are not comprehensive, may not last over a lifetime and can be achieved by other preventive health measures, which do not involve a
surgical procedure.
The GRADE system is an appropriate method to employ when the evidence is
variable in quality and generalizability 2. We did not perform a GRADE effects
calculation analyses for our outcomes but used the methodology to objectively classify
the quality of evidence we present to support our recommendations (Table 2). A decision
to proceed with neonatal MC requires a thorough discussion on the pros and cons of the
procedure. This would allow parents contemplating a MC to make a well-informed
choice. Given the socio-economic, educational status and health demographics of our
population, universal neonatal circumcision cannot be justified based on the current
evidence available.
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Figures and Tables
Fig 1. Pathological phimosis.

Fig 2. Balano-posthitis.
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Fig 3. Lichen sclerosus of the foreskin.

Fig 4. Hypospadias .
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Fig 5. Epispadias.

Fig 6. Peno-scrotal webbing.
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Fig 7. Concealed penis.

Fig 8. Ventral curvature.

Fig 9. Megameatus intact prepuce hypospadias variant.
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Table 1. The three randomized trials on circumcision and HIV prevention
Study
(location,
time
period)
Auvert et
al (South
Africa,
2002‒
2005)

Allocation
concealment

Blinding

Inclusion
criteria

n

Followup

Lost to
followup

AEs

Outcomes

ITT RR
(95% CI)

As treated
RR
(95% CI)

Covariate
adjusted
RR

Partial

Study
personnel

Male 18‒24,
wishing to
be
circumcised

3274

251 (8%)
30% in
circumcised
and 33%
uncircumcised

3.8%

Intervention: 20/1546
Control: 49/1582

0.42
(0.25‒0.70)

0.24
(0.14‒0.44)

0.39
(0.23‒0.66)

Bailey et
al (Kenya,
2002‒
2006)

Unclear

HIV testers
Nurses
counselling
and doing
questionnaires
partially
blinded

HIVnegative,
18‒24 years

2784

Stopped at
63% of
total
anticipated
personyears
Stopped at
87%
followup

1.7%

Intervention: 22/1388
Control: 47/1392

0.47
(0.28‒0.78)

0.45
(0.27‒0.76)

0.44‒0.47

Gray et al
(Uganda
2002‒
2006)

Partial

None specified

HIVnegative,
15‒49 years

4996

86% (1501)
completed 24
month
followup,
overall
1283/2784
(46%) did not
complete trial
22% at 24
months
followup

8%

Intervention: 22/2387
Control: 45/2430

0.49
(0.28‒0.84)

0.45
(0.25‒0.78)

0.49
(0.29‒0.81)

Stopped at
72%
persontime
accrual
AE: adverse events; CI: confidence interval; ITT: intention-to-treat; RR: relative risk.
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Table 2. Benefits of circumcision classified by GRADE recommendations
Clinical
Direction of
Amount of
Level of
GRADE
benefit
evidence
effect
evidence
quality of
evidence
Decreased
Positive
0.07‒0.23
Level 2
Low quality
risk of UTI
Decreased
Positive
0.34‒0.62
Level 1
High quality
risk of HIV
Decreased
Positive
0.57‒ 0.77
Level 1
Moderate
risk of HPV
quality
prevalence
Decreased
Unclear
NS
Level 2
Low quality
risk of HPV
incidence
Decreased
Positive
0.36‒0.91
Level 2
Moderate
risk of HSV
quality
Decreased
Positive
0.13‒0.83
Level 2
Low quality
risk of penile
cancer
*
Concerns related to external validity of data for Canadian population. HPV: human
papilloma virus; HSV: herpes simplex virus; UTI: urinary tract infection.

GRADE
strength of
recommendation
Weak
Strong*

Weak

Weak

Weak
Weak
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Table 3. Summary results for level 1-2 evidence benefits of circumcision classified by GRADE
recommendations
Clinical
Direction of
Amount of
Level of
GRADE
GRADE
benefit
evidence
effect
evidence
quality of
strength of
evidence
recommendation
Decreased
Positive
0.07-0.23
Level 2
Low quality
Weak
risk of UTI
Decreased
Positive
0.34-0.62
Level 1
Strong*
High quality
risk of HIV
Decreased
Positive
0.57- 0.77
Level 1
Moderate
Weak
risk of HPV
Prevalence
quality
prevalence
rate ratio
Decreased
Unclear
NS
Level 2
Low quality
Weak
risk of HPV
incidence
Decreased
Positive
0.36-0.91
Level 2
Moderate
Weak
risk of HSV
quality
Weak
Positive
0.13-0.83
Low quality
Decreased
Level 2
risk of
penile
cancer
*

Uncertainty related to: 1) effects of neonatal circumcision in Canadian setting; 2)
whether circumcision represents a wise use of resources compared to other preventive
strategies; 3) the balance of advantages versus risks of circumcision given the uncertainty
of circumcision risks. HPV: human papilloma virus; HSV: herpes simplex virus; UTI:
urinary tract infection.
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